Literature DB >> 11388582

Improved sentinel node visualization in breast cancer by optimizing the colloid particle concentration and tracer dosage.

R A Valdés Olmos1, P J Tanis, C A Hoefnagel, O E Nieweg, S H Muller, E J Rutgers, M L Kooi, B B Kroon.   

Abstract

Faint lymph uptake may hamper sentinel node (SN) identification by scintigraphy and subsequent gamma probe localization. The aim of the present study was to evaluate an adjustment in the colloid particle concentration and tracer dosage to optimize mammary lymphoscintigraphy. Scintigraphy was performed in 151 patients with a palpable breast carcinoma and clinically negative axilla: for the first 75 patients (group A) a standard labelling of 0.5 mg nanocolloid with 99Tcm was performed, for the subsequent 76 patients (group B) the labelling dilution volume was reduced from 4 to 2 ml. For both groups the volume of injection was 0.2 ml. Lymph node uptake was evaluated by a 4-step visual score (from 0 = absent to 3+ = very intense), and by count quantification of at 4 h in the first draining SN. The SN visualization rate increased from 93% (70/75) in group A (mean dosage 93.4 MBq, range 57-130 MBq) to 99% (75/76) in group B (mean dosage 106.5 MBq, range 74-139 MBq). The percentage of patients with uptake 3+ was significantly higher (P = 0.001) in group B (51% vs 35% in group A). SN counts were significantly higher for group B (P<0.001). The percentage of patients with less than 2000 counts/node diminished from 45% in group A to 9% in group B (P = 0.001). In group B (P = 0.033) more lymph channels (53% vs 35% in group A) were visualized and for a longer time (26% vs 4% at 4 h). Axillary drainage was seen in 96% in group A and 98% in group B whereas non-axillary drainage was observed in 19% and 25%, respectively. Intraoperative SN identification rate was 97% in group A and 100% in group B. SN metastases were found in 41% of group A and 47% of group B. It is concluded that enhancement of colloid particle concentration and adjustment of tracer dosage led to improved SN identification by substantial increase in lymph node uptake and lymph vessel depiction. A significant reduction of cases with faint SN uptake enables better surgical efficacy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11388582     DOI: 10.1097/00006231-200105000-00018

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  14 in total

1.  Effect of increased 99mTc/99Tc ratios on count rates in sentinel node procedures: a randomised study.

Authors:  James R Ballinger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

2.  The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer.

Authors:  Iris M C van der Ploeg; Omgo E Nieweg; Bin B R Kroon; Emiel J T Rutgers; Marie-Jeanne T F D Baas-Vrancken Peeters; Wouter V Vogel; Cornelis A Hoefnagel; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-13       Impact factor: 9.236

3.  Response to comment by Aprile et al.: the EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer.

Authors:  F Giammarile; N Alazraki; J N Aarsvold; R A Audisio; E Glass; S F Grant; J Kunikowska; M Leidenius; V M Moncayo; R F Uren; W J Oyen; R A Valdés Olmos; S Vidal Sicart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-26       Impact factor: 9.236

4.  Factors of importance for scintigraphic non-visualisation of sentinel nodes in breast cancer.

Authors:  A H Chakera; E Friis; U Hesse; N Al-Suliman; B Zerahn; B Hesse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-05       Impact factor: 9.236

5.  Optimizing the colloid particle concentration for improved preoperative and intraoperative image-guided detection of sentinel nodes in prostate cancer.

Authors:  Lenka Vermeeren; Sara H Muller; Willem Meinhardt; Renato A Valdés Olmos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

6.  Subareolar injection of technetium-99m nanocolloid yields reliable data on the axillary lymph node tumour status in breast cancer patients with previous manipulations on the primary tumour: a prospective study of 117 patients.

Authors:  Sofiane Maza; Anke Thomas; Klaus J Winzer; Christine Hüttner; Jens-Uwe Blohmer; Maik Hauschild; Matthias Richter; Thomas Krössin; Lilli Geworski; Andreas Zander; Hans Guski; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-27       Impact factor: 9.236

7.  Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer.

Authors:  B E Schaafsma; F P R Verbeek; D D D Rietbergen; B van der Hiel; J R van der Vorst; G J Liefers; J V Frangioni; C J H van de Velde; F W B van Leeuwen; A L Vahrmeijer
Journal:  Br J Surg       Date:  2013-05-21       Impact factor: 6.939

8.  Effect of increased (99m)Tc/(99)Tc ratios on count rates in sentinel node procedures: a randomised study.

Authors:  G M M Gommans; F M van der Zant; T G van der Schors; A van Dongen; G J J Teule; W W J Clarijs; B L A M Langenhorst; J W D de Waard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-25       Impact factor: 9.236

9.  The hidden sentinel node and SPECT/CT in breast cancer patients.

Authors:  Iris M C van der Ploeg; Renato A Valdés Olmos; Bin B R Kroon; Emiel J T Rutgers; Omgo E Nieweg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-20       Impact factor: 9.236

10.  One-day or two-day procedure for sentinel node biopsy in melanoma?

Authors:  A H Chakera; J Lock-Andersen; U Hesse; B M Nürnberg; B R Juhl; K H Stokholm; K T Drzewiecki; B Hesse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.